Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study

Table 5 Sensitivity analysis

Cancer	Group	HR (95%CI)
		Model 1	Model 2	Model 3
Liver	Quartile 1	1.00 (reference)	1.00 (reference)	1.00 (reference)
	Quartile 2	1.00 (0.64-1.55)	1.01 (0.65-1.57)	0.92 (0.59-1.43)
	Quartile 3	0.78 (0.49-1.24)	0.79 (0.50-1.25)	0.68 (0.42-1.08)
	Quartile 4	1.04 (0.66-1.63)	1.04 (0.66-1.63)	0.82 (0.51-1.31)
Gallbladder	Quartile 1	1.00 (reference)	1.00 (reference)	1.00 (reference)
	Quartile 2	1.68 (0.66-4.28)	1.71 (0.67-4.36)	1.63 (0.63-4.21)
	Quartile 3	1.41 (0.51-3.89)	1.42 (0.52-3.93)	1.31 (0.46-3.72)
	Quartile 4	2.71 (1.02-7.21)	2.72 (1.03-7.23)	2.40 (0.85-6.80)
Biliary tract	Quartile 1	1.00 (reference)	1.00 (reference)	1.00 (reference)
	Quartile 2	1.09 (0.48-2.47)	1.10 (0.49-2.51)	1.12 (0.48-2.61)
	Quartile 3	1.10 (0.48-2.50)	1.14 (0.50-2.60)	1.08 (0.46-2.55)
	Quartile 4	0.75 (0.31-1.82)	0.79 (0.32-1.93)	0.68 (0.26-1.75)
Pancreas	Quartile 1	1.00 (reference)	1.00 (reference)	1.00 (reference)
	Quartile 2	1.26 (0.90-1.76)	1.26 (0.90-1.77)	1.25 (0.89-1.76)
	Quartile 3	1.76 (1.27-2.44)	1.77 (1.28-2.46)	1.71 (1.22-2.40)
	Quartile 4	2.09 (1.49-2.92)	2.11 (1.51-2.95)	1.96 (1.38-2.80)

Model 1 adjusted for genders, age, education, ethnic group and family history of cancer. Model 2 adjusted for genders, age, education, ethnic group, family history of cancer, alcohol intake, smoking status, annual household income, fruit and vegetable intake and physical activity. Model 3 additionally adjusted for body mass index based on model 2. Participants with less than 2 yrs of follow-up were excluded. HR: Hazard ratio; CI: Confidence interval.